Recap: Arrowhead Pharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
Arrowhead Pharma (NASDAQ:ARWR) reported Q4 earnings with an EPS of $-1.02, missing estimates by 70% compared to the expected $-0.6. Revenue decreased by $15.48 million from the same period last year. The company's stock price dropped 10.78% the day after missing EPS estimates last quarter. Historical earnings performance shows inconsistency in meeting EPS estimates.
November 29, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arrowhead Pharma reported a larger than expected Q4 earnings loss and a decrease in revenue, which may lead to a negative short term impact on its stock price.
Given the significant miss in earnings expectations and the historical reaction of a 10.78% stock price drop after the last earnings miss, it is likely that ARWR's stock price will experience a similar negative impact in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100